| 000 | 01767 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516205315.0 | ||
| 264 | 0 | _c20150105 | |
| 008 | 201501s 0 0 eng d | ||
| 022 | _a1651-226X | ||
| 024 | 7 |
_a10.3109/0284186X.2014.892210 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTengström, Maria | |
| 245 | 0 | 0 |
_aMnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen. _h[electronic resource] |
| 260 |
_bActa oncologica (Stockholm, Sweden) _cJun 2014 |
||
| 300 |
_a769-75 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aSuperoxide Dismutase _xgenetics |
| 650 | 0 | 4 |
_aTamoxifen _xtherapeutic use |
| 650 | 0 | 4 |
_aXeroderma Pigmentosum Group D Protein _xgenetics |
| 700 | 1 | _aMannermaa, Arto | |
| 700 | 1 | _aKosma, Veli-Matti | |
| 700 | 1 | _aSoini, Ylermi | |
| 700 | 1 | _aHirvonen, Ari | |
| 700 | 1 | _aKataja, Vesa | |
| 773 | 0 |
_tActa oncologica (Stockholm, Sweden) _gvol. 53 _gno. 6 _gp. 769-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/0284186X.2014.892210 _zAvailable from publisher's website |
| 999 |
_c23722352 _d23722352 |
||